Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study

Neurology

Volumn 83, Issue 1, 2014, Pages 78-86

  O'Connor, Paul ^a   Goodman, Andrew ^b   Kappos, Ludwig ^c   Lublin, Fred ^d   Polman, Chris ^e   Rudick, Richard A ^f   Hauswirth, Kathy ^g   Cristiano, Lynda M ^h   Forrestal, Fiona ^h   Duda, Petra ⁱ  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Infusion Communications Inc   (United States)

^h BIOGEN   (United States)

ⁱ AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BENIGN TUMOR; BREAST DISEASE; CAUSE OF DEATH; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG REEXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART INFARCTION; HEPATOBILIARY DISEASE; HUMAN; IMMUNOTHERAPY; INFESTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RESPIRATORY TRACT DISEASE; SUICIDE; THORAX DISEASE; URINARY TRACT INFECTION; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OBSERVATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903964778     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000541     Document Type: Article

References (22)

1. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356: 63-66.
2. Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol 2013;70: 172-182.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354: 899-910.
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354: 911-923.
5. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) Study. Lancet Neurol 2009;8: 254-260.
6. Pellegrini F, Belachew S, Butzkueven H, et al. Longterm safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI® observational programme. Mult Scler 2012;18: 220-221. P519.
7. US Food and Drug Administration. Public health advisory: suspended marketing of Tysabri (natalizumab). Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ DrugSafetyInformationfor HeathcareProfessionals/PublicHealthAdvisories/ ucm051761.htm. Accessed November 6, 2013.
8. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353: 369-374.
9. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353: 375-381.
10. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353: 362-368.
11. TYSABRI® (natalizumab). Summary of product characteristics. Available at: http://www.medicines.org.uk/emc/document.aspx? documentid518447&docType5SPC. Accessed November 6, 2013.
12. TYSABRI® (natalizumab) [package insert]. Cambridge, MA: Biogen Idec Inc.; 2013.
13. Outteryck O, Ongagna JC, Zephir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 2010;257: 207-211.
14. Fernandez O, Oreja-Guevara C, Arroyo R, Izquierdo G, Perez JL, Montalban X. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 2012;259: 1814-1823.
15. Kallweit U, Jelcic I, Braun N, et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol 2012;35: 77-80.
16. Biogen Idec. Medical information. Available at: https://medinfo. biogenidec.com/medinfo/. Accessed March 11, 2013.
17. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebocontrolled study. Neurology 2009;72: 806-812.
18. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-1403.
19. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366: 1870-1880.
20. Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011;17: 372-375.
21. Cree B, DeSeze J, Fox R. RESTORE study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity. Neurology 2012;78: P06.168.
22. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76: 1858-1865.